| Stereochemistry | MIXED |
| Molecular Formula | C24H32N2O2 |
| Molecular Weight | 380.5231 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C3=CC=CC=C3
InChI
InChIKey=BSHWLCACYCVCJE-UHFFFAOYSA-N
InChI=1S/C24H32N2O2/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22/h4-13,20,23H,3,14-19H2,1-2H3
| Molecular Formula | C24H32N2O2 |
| Molecular Weight | 380.5231 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Eprazinone has been variously described as having mucolytic or expectorant properties as well as a direct relaxant action on bronchial smooth muscle and it suppress the excitation of cough center to stop coughing. It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia The most commonly reported adverse reactions include loss of appetite, nausea/vomiting, stomach discomfort, diarrhea (including loose stool) and symptom of irritation.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
take 60-90mg of the active ingredient in 3 divided doses a day
Route of Administration:
Other
